Beginning the Journey - diagnosed 0-3 years

Clear all

CureDuchenne Webinar with Wave Life Sciences

Wave will provide an overview of initial clinical trial results for WVE-N531 in individuals with Duchenne muscular dystrophy who are amenable to exon 53 skipping, as well as an overview of the potentially registrational FORWARD-53 study. 

Anne-Marie Li-Kwai-Cheung, MChem, MTOPRA, RAPS

Chief Development Officer

Wave Life Sciences

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

DMD Clinical Trials: An Overview

This resource presents information on the clinical trial process, common clinical trial terms, updated trial processes due to telehealth, and more.

Lauren Morgenroth, MS, CGC

Chief Operating Officer

TRiNDS

Ana Christensen, MPH

Lead Project Manager, Strategic Solutions

TRiNDS